Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Rhea-AI Summary

Kazia Therapeutics (NASDAQ: KZIA) announced a private placement (PIPE) offering of approximately $50.0 million of ordinary shares and pre-funded warrants at an ADS-equivalent price of $5.00 per ADS (one ADS = 500 ordinary shares). The financing is led by healthcare-dedicated investors and expected to close on December 3, 2025, subject to customary conditions.

Net proceeds are expected to be about $46.5 million after fees and expenses, intended to fund continued clinical development of paxalisib, advance the PD-L1 degrader program, and for general corporate purposes; cash runway is expected into the second half of 2028.

Positive

• $50.0 million PIPE financing announced
• Net proceeds of approximately $46.5 million
• Cash runway extended into 2H 2028
• Proceeds allocated to paxalisib and PD-L1 degrader programs

Negative

• Equity issuance will dilute existing shareholders
• Placement agent fees and expenses reduce gross proceeds to $46.5 million
• Closing is subject to customary conditions and may not occur on expected date
• Resale of securities requires shelf registration filed within 30 days

News Market Reaction – KZIA

+9.95%

42 alerts

+9.95% Session close to close

+52.7% Peak Tracked

-20.8% Trough Tracked

$22.36M Market Cap

0.3x Rel. Volume

In the Dec 2 session, KZIA gained 9.95%, reflecting a notable positive market reaction. Argus tracked a peak move of +52.7% during that session. Argus tracked a trough of -20.8% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +9.9% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +9.9% in the session following this news. A strong positive reaction aligns with the company’s need to secure funding for its oncology pipeline, especially after prior disclosures of limited cash runway and Nasdaq listing pressure. Investors previously reacted constructively to some financings and clinical milestones, but past divergences on good news highlight execution and regulatory risks. As additional capital comes in, future performance could depend on how efficiently proceeds are deployed into paxalisib and the PD‑L1 degrader programs.

Key Figures

PIPE size: $50.0 million PIPE net proceeds: $46.5 million ADS price: $5.00 per ADS +3 more

6 metrics

PIPE size $50.0 million Aggregate private placement of ordinary shares and pre-funded warrants

PIPE net proceeds $46.5 million Expected net after placement agent fees and offering expenses

ADS price $5.00 per ADS Purchase price per ADS equivalent in the PIPE

ADS share ratio 500 ordinary shares per ADS Each ADS represents 500 ordinary shares

Cash runway Second half of 2028 Runway expectation combining PIPE proceeds and existing cash

Closing date December 3, 2025 Expected closing date of the PIPE, subject to conditions

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 10	Clinical data update	Positive	-17.8%	Translational and early clinical data showing paxalisib activity in advanced breast cancer.
Dec 02	Private placement	Positive	+9.9%	Approximately $50M PIPE to fund paxalisib, PD-L1 degrader, and extend cash runway.
Nov 18	Clinical and business update	Positive	-5.3%	Initial iCR in metastatic TNBC plus pipeline and Nasdaq listing status update.
Oct 27	Regulatory strategy	Positive	+4.6%	Plan to request FDA Type C meeting on GBM survival data and potential NDA path.
Oct 07	Licensing deal	Positive	+5.3%	Exclusive in-licensing of first‑in‑class PD-L1 protein degrader program from QIMR.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: positive clinical and financing news sometimes aligned with gains, but two major positive updates (including paxalisib data) coincided with sharp selloffs, indicating occasional negative divergence on good news.

Recent Company History

Over the last few months, Kazia reported multiple paxalisib advances in GBM and breast cancer, including survival data and an initial immune-complete response, alongside in-licensing of a PD-L1 degrader. It also faced Nasdaq MVLS noncompliance. Financing has been recurring, with earlier smaller PIPEs and this larger $50.0M deal to extend cash runway into the second half of 2028. The current private placement fits a pattern of raising capital to fund an expanding oncology pipeline amid listing compliance pressures.

Key Terms

private placement, pipe, prefunded warrants, ads, +3 more

7 terms

private placement financial

"for a private placement of equity securities (PIPE)."

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pipe financial

"for a private placement of equity securities (PIPE)."

A PIPE (private investment in public equity) is a deal in which institutional or accredited investors buy shares or convertible securities directly from a publicly traded company, usually at a discount to the market price. Companies use PIPEs to raise money faster than through a traditional public offering; for existing shareholders they matter because the newly issued shares add to the share count and can dilute ownership.

prefunded warrants financial

"ordinary shares and prefunded warrants, at a purchase price per share"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

ads financial

"equivalent of $5.00 per ADS, each ADS representing 500 ordinary shares."

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

pi3k/mtor inhibitor medical

"paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials"

A PI3K/mTOR inhibitor is a drug that blocks two important proteins cells use to send growth and survival signals, like turning off both the power and the thermostat in a building to stop uncontrolled activity. Investors watch these drugs because if they safely slow or stop tumor growth they can become valuable treatments, but progress depends heavily on clinical trial results, safety profiles and regulatory approval.

pdl1 degrader medical

"advancing the PD-L1 degrader program, and for general corporate purposes."

A PD‑L1 degrader is a drug designed to reduce or remove the PD‑L1 protein that some cancer cells use to hide from the immune system. Think of it like taking down a “do not disturb” sign so the body’s immune cells can see and attack tumors more easily. For investors, degraders represent an alternative to current immune‑checkpoint drugs with the potential for different effectiveness, safety profiles and commercial value in oncology.

prospectus regulatory

"Any offering of the securities described above under the resale registration statement will only be by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to the investors an aggregate of approximately $50.0 million of ordinary shares and prefunded warrants, at a purchase price per share that is the equivalent of $5.00 per ADS, each ADS representing 500 ordinary shares. The PIPE is structured as a straightforward equity investment with no common warrant coverage. The PIPE financing was led by healthcare-dedicated investors including Adar1 Capital Management LLC, Ikarian Capital LLC, Stonepine Capital Management, Velan Capital Investment Management LP, and Revach Capital Management, LLC, alongside existing shareholders, including Jorey Chernett. The transaction is expected to close on Wednesday, December 3, 2025, subject to customary closing conditions.

Konik Capital Partners, LLC is acting as the exclusive placement agent for the PIPE.

The net proceeds to the Company from the PIPE are expected to be approximately $46.5 million, after deducting placement agent's fees and other estimated offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to support the continued clinical development of its lead program paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for both brain cancer and advanced breast cancer, advancing the PD-L1 degrader program, and for general corporate purposes. The Company expects the net proceeds from the PIPE, combined with the existing cash and cash equivalents, will extend its cash runway into the second half of 2028.

The securities sold in this PIPE are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements. Pursuant to the securities purchase agreement, the Company has agreed to file a shelf registration statement with the U.S. Securities and Exchange Commission (SEC) within 30 days of the closing to register the resale of ADSs representing the ordinary shares and those underlying the pre-funded warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the securities described above under the resale registration statement will only be by means of a prospectus.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor, which is being developed to treat multiple forms of brain cancer, including glioblastoma and brain metastases. A Phase 1b clinical trial is also underway evaluating paxalisib in combination with checkpoint inhibition and chemotherapy for patients with advanced triple-negative breast cancer. EVT801, a selective VEGFR3 inhibitor, is currently in a Phase 1 clinical trial for advanced solid tumors. Kazia is working to rapidly progress these assets through clinical development and toward commercialization.

Forward Looking Statements

This announcement may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the completion of the PIPE, the satisfaction of customary closing conditions related thereto, the intended use of proceeds from the PIPE, the anticipated extension of the Company's cash runway into the second half of 2028 following completion of the PIPE, and the Company's future expectations, plans and prospects. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: related to market and other conditions, associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's most recent Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. Investors should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

For further information contact:

Alex Star
Managing Director
LifeSci Advisors LLC
Astarr@lifesciadvisors.com
Ph: +1 (201) 786-8795

View original content:https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-pricing-of-50-0-million-private-placement-of-equity-securities-302630502.html

SOURCE Kazia Therapeutics Limited

FAQ

How much did Kazia (KZIA) raise in the December 2, 2025 PIPE offering?

Kazia announced an aggregate PIPE of $50.0 million in ordinary shares and pre-funded warrants.

What are the expected net proceeds to Kazia (KZIA) from the PIPE closing Dec 3, 2025?

Net proceeds are expected to be approximately $46.5 million after placement agent fees and offering expenses.

How will the KZIA PIPE proceeds be used and what programs are funded?

Proceeds are intended to fund continued clinical development of paxalisib, advance the PD-L1 degrader program, and for general corporate purposes.

How long will Kazia's cash runway last after the $50M PIPE (KZIA)?

The company expects the PIPE proceeds plus existing cash to extend its cash runway into the second half of 2028.

When is the KZIA PIPE expected to close and what conditions apply?

The transaction is expected to close on December 3, 2025, subject to customary closing conditions.

Will the PIPE issuance require shareholder resale registration for KZIA securities?

Yes; Kazia agreed to file a shelf registration statement with the SEC within 30 days of closing to register resale of the securities.